N4 Pharma Plc provided a further successful update on its ongoing research work into the use of Nuvec®? to enhance the performance of viral vectors. Through its research programme with the University of Brunel, the Company has demonstrated via a series of in vitro experiments that Nuvec®?

can deliver increased transduction efficacy, when complexed with Adeno-Associated virus 8 ("AAV8"). This follows on from earlier work where the Company showed that Nuvec®? increased transduction efficacy of a standard Adenovirus vector.

Specifically, Nuvec®? was mixed with AAV8 carrying a fluorescent green protein gene and used to transduce human-like liver cells (induced pluripotent cell model). When the viral vector was complexed with Nuvec®?, transduction efficacy increased 2.5-fold compared to the AAV8 vector when used on a standalone basis.

AAV8 was chosen for investigation as this virus is currently being used for products already in clinical development.